The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | CLL trial updates: ALLIANCE & iLLUMINATE
Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, discusses the results of major chronic lymphocytic leukemia (CLL) trials from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Eichhorst then summarizes what the implications of these trials are in terms of the use of ibrutinib.
